Health Catalyst (NASDAQ:HCAT) Shares Up 8% After Analyst Upgrade

Health Catalyst, Inc. (NASDAQ:HCAT) shares traded up 8% during mid-day trading on Wednesday after Citigroup raised their price target on the stock from $9.00 to $10.50. Citigroup currently has a buy rating on the stock. Health Catalyst traded as high as $8.83 and last traded at $8.78. 84,323 shares were traded during mid-day trading, a decline of 85% from the average session volume of 561,146 shares. The stock had previously closed at $8.13.

HCAT has been the topic of several other reports. Royal Bank of Canada upped their price objective on shares of Health Catalyst from $8.00 to $9.00 and gave the company a “sector perform” rating in a report on Thursday, November 7th. Evercore ISI upped their price target on shares of Health Catalyst from $8.00 to $10.00 and gave the company an “outperform” rating in a research note on Tuesday, October 8th. Cantor Fitzgerald reiterated an “overweight” rating and issued a $16.00 price objective on shares of Health Catalyst in a research note on Friday, October 4th. Piper Sandler dropped their target price on Health Catalyst from $14.00 to $11.00 and set an “overweight” rating on the stock in a research report on Monday, August 26th. Finally, Stephens reduced their price target on Health Catalyst from $8.00 to $7.00 and set an “equal weight” rating for the company in a research report on Thursday, August 8th. Three equities research analysts have rated the stock with a hold rating and nine have given a buy rating to the company’s stock. According to data from MarketBeat.com, Health Catalyst has an average rating of “Moderate Buy” and a consensus price target of $11.54.

Insider Transactions at Health Catalyst

In related news, COO Daniel Lesueur sold 8,137 shares of the business’s stock in a transaction that occurred on Wednesday, September 4th. The stock was sold at an average price of $7.58, for a total value of $61,678.46. Following the completion of the sale, the chief operating officer now owns 140,108 shares in the company, valued at $1,062,018.64. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. In other Health Catalyst news, insider Kevin Lee Freeman sold 7,500 shares of the business’s stock in a transaction dated Tuesday, September 3rd. The shares were sold at an average price of $7.22, for a total value of $54,150.00. Following the transaction, the insider now owns 255,881 shares in the company, valued at approximately $1,847,460.82. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, COO Daniel Lesueur sold 8,137 shares of Health Catalyst stock in a transaction that occurred on Wednesday, September 4th. The stock was sold at an average price of $7.58, for a total value of $61,678.46. Following the completion of the sale, the chief operating officer now owns 140,108 shares in the company, valued at approximately $1,062,018.64. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 35,396 shares of company stock valued at $266,280. Insiders own 2.50% of the company’s stock.

Institutional Investors Weigh In On Health Catalyst

Large investors have recently modified their holdings of the stock. Principal Financial Group Inc. lifted its holdings in Health Catalyst by 6.9% in the second quarter. Principal Financial Group Inc. now owns 29,469 shares of the company’s stock worth $188,000 after buying an additional 1,907 shares during the period. Harbor Capital Advisors Inc. lifted its stake in shares of Health Catalyst by 21.3% in the 3rd quarter. Harbor Capital Advisors Inc. now owns 11,764 shares of the company’s stock valued at $96,000 after purchasing an additional 2,064 shares during the period. The Manufacturers Life Insurance Company grew its stake in Health Catalyst by 10.3% in the second quarter. The Manufacturers Life Insurance Company now owns 23,162 shares of the company’s stock worth $148,000 after purchasing an additional 2,164 shares during the period. Creative Planning raised its holdings in Health Catalyst by 13.2% in the third quarter. Creative Planning now owns 21,348 shares of the company’s stock worth $174,000 after purchasing an additional 2,486 shares in the last quarter. Finally, Quarry LP lifted its position in Health Catalyst by 59.4% during the second quarter. Quarry LP now owns 7,002 shares of the company’s stock valued at $45,000 after buying an additional 2,610 shares during the period. Institutional investors own 85.00% of the company’s stock.

Health Catalyst Stock Up 6.6 %

The stock has a market capitalization of $527.57 million, a PE ratio of -6.55 and a beta of 1.32. The stock’s 50-day moving average price is $8.11 and its two-hundred day moving average price is $7.19. The company has a debt-to-equity ratio of 0.32, a quick ratio of 1.41 and a current ratio of 1.41.

Health Catalyst (NASDAQ:HCAT) last posted its quarterly earnings results on Wednesday, November 6th. The company reported $0.07 earnings per share for the quarter, missing the consensus estimate of $0.10 by ($0.03). The company had revenue of $76.40 million during the quarter, compared to analysts’ expectations of $76.27 million. Health Catalyst had a negative return on equity of 7.51% and a negative net margin of 26.20%. The business’s quarterly revenue was up 3.5% on a year-over-year basis. During the same quarter in the previous year, the company earned ($0.22) EPS. As a group, analysts expect that Health Catalyst, Inc. will post -0.35 EPS for the current fiscal year.

About Health Catalyst

Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations in the United States. It operates in two segments, Technology and Professional Services. The company provides data operating system data platform which provides clients single comprehensive environment to integrate and organize data from their disparate software systems; and analytics applications, a software analytics applications build for data platform to analyze clients face across clinical and quality, population health, and financial and operational use cases.